Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Chimeric Therapeutics - Clinical milestones for 2024 & 2023 successes highlighted (ASX:CHM)

-- Reported positive preliminary data for CHM 1101 in heavily pretreated glioblastoma patients, confirming advancement to next phase of CHM 1101 development -- FDA IND clearance for CHM 2101 enabli...read more

Chimeric Therapeutics - Half Yearly Report and Accounts (ASX:CHM)

To view the report, download the attached PDF.

Chimeric Therapeutics - 1st patient treated in ADVENT-AML Phase 1b clinical trial (ASX:CHM)

ADVENT-AML is the first clinical trial to evaluate NK cell therapy in combination with the current standard of care for Acute Myeloid Leukemia (AML) patients The trial, no...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Sydney, Australia, 31 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its...read more

Chimeric Therapeutics - Placement of Entitlement Offer Shortfall (ASX:CHM)

-- Placement of Entitlement Offer Shortfall of approx. $3.20m from institutional and sophisticated investors -- Takes the total amount subscribed under the entitlement offer and entitlement offer s...read more

Chimeric Therapeutics - ADVENT-AML Phase 1B clinical trial open to enrolment (ASX:CHM)

-- ADVENT-AML (CHM 0201 + Azacitidine + Venetoclax) Phase 1B clinical trial now open to enrollment at The University of Texas MD Anderson Cancer Center -- Enrolment open to patients with relapsed /...read more

Chimeric Therapeutics receives $7.36M R&D tax incentive (ASX:CHM)

Sydney, Australia, 10 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell, is pleased announce it has received a research...read more

Chimeric Therapeutics - Completion of Entitlement Offer (ASX:CHM)

On 25 October 2023, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximately $10 million...read more

Chimeric Therapeutics - Positive in vitro data for CHM 1301 CAR NK cells (ASX:CHM)

Positive preclinical data for CHM 1301, a next generation off the shelf CLTX CAR NK cell therapy Up to 300% enhanced cell killing demonstrated compared to first generation NK c...read more

Chimeric Therapeutics - 1st patient dosed in Phase 1b recurrent glioblastoma trial (ASX:CHM)

1st patient dosed in the Phase 1B with CHM 1101 in brain cancer clinical trial The Phase 1B clinical trial builds off the recent positive Phase 1A clinical data Phase 1B ...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30...read more

Chimeric Therapeutics - FDA clearance of IND for CHM 2101 (ASX:CHM)

FDA IND Clearance for CHM 2101, a novel 3rd generation CDH17 CAR T cell therapy Anticipated to be the first CDH17 CAR T cell therapy to enter the clinic Phase 1A clinical...read more

Chimeric Therapeutics - New data for Phase 1A CLTX CAR T brain cancer clinical trial (ASX:CHM)

A 55% Disease Control Rate (DCR) was achieved in patients treated with CLTX CAR T, exceeding historical disease control rates of 20-37%1 ~10 months median survival was demonstr...read more

Chimeric Therapeutics - Agreement with MD Anderson for Phase 1B CHM 0201 AML study (ASX:CHM)

Investor webinar with the Principal Investigator of the trial, Dr Abhishek Maiti, to be held at 11am AEST Thursday 14 September. Register here. Sydney, Australia, 13 September 2...read more

Chimeric Therapeutics - Appendix 4E and Preliminary Final Report (ASX:CHM)

To view the appendix, download the attached PDF.

Viewing: 1 - 15 of 88 Previous | Next